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The treatment and prevention of acute ischemic stroke
Protecting the brain from the consequences .ofvascular obstruction is obviously very important.However, how to manage this is a very complex
task. Three recent studies have provided evidence that
should not be ignored or misinterpreted by physicians.I-3
The National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Groupl shows the results of a
randomized, collaborative placebo-controlled trial. Six
hundred and twenty-four patients were studied. The
treatment was started before 90' of the start of the stroke
or before 180'. Patients received recombinant rt-PA
(alteplase) 0.9 mg/kg or placebo. A careful neurological
evaluation was done at 24 hours and 3 months after the
stroke.
There were no significant differences between the
groups at 24 hours after the stroke. The evaluation done
at 3 months showed that there were more patients in the
treated group with minimal to no disability than in the
placebo group (50% vs. 38% p<0.03).
In other words, lout of 8 treated patients was spared
a neurological disability. On the other hand, symptomatic
intracerebral haemorrhage was ten times more frequent in
the group that received rt-PA (6.4%) than in the control
(0.6%) p< 0.001.
Another study, Low-molecular weight Heparin
(LMWH) for the Treatment of Acute Ischemic Stroke,2
compared subcutaneous injections of low-molecular
heparin, 4100 antifactor Xa IV of nadroparin calcium in
0.4 ml of solution every 12 hours (higher dose), LMWH
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alternated with placebo (lower dose) and placebo injections
every 12 hours, for 10 days. The evaluation at 6 months
showed that the treated group had a lower incidence rate
of poor outcomes, death or dependency in daily activities,
45 vs. 65%. In other words, it was necessary to treat 5
patients to benefit one. Evaluations at 10 days did not show
differences in death rates or haemorrhage transformation
of the cerebral infarction.
The Multicentre Acute Stroke Trial-Italy (MAST-I)
Group compared the effectiveness of streptokinase, aspirin
and a combination of both for the treatment of ischemic
stroke. Six hundred and twenty-two patients were
randomized to receive I hour infusions of 1.5 mD of
streptokinase alone, the same dose of streptokinase plus
300 mg of buffered aspirin, or 300 mg of aspirin alone for
10 days, or nothing. The case fatality rate was higher in
the groups treated with streptokinase alone, or
streptokinase plus aspirin, than in the group that received
only aspirin or nothing.
Inspite of all this information, more studies are
necessary to establish safe and effective guidelines for the
treatment of schemic stroke. It appears that aspirin and
low-molecular weight heparin are safe, but new studies
are necessary to compare aspirin with LMWH and with
rt-PA.
This will require collaborative studies, and then good
randomized trials must be analyzed as a whole using a
systematic review. Interested readers may refer to a very
interesting commentary by Longstreth in Evidence Based
Medicine.4 Although the best treatment for ischemic stroke
it not yet well established, its prevention is more clear.
Treatment of arterial hypertension, particularly in the
elderly,S and the long standing use of low-dose aspirin in
high-risk patients brings benefits.6 In regards to ischemic
stroke, as usual, prevention is better than treatment.
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